Nazneen Aziz,
Director,
College of American Pathologists
Nazneen Aziz is the Director of Molecular Medicine at the College of American Pathologists. In this role, Dr. Aziz is responsible for initiating and guiding genomic strategies and projects at CAP. Dr. Aziz is leading several projects at CAP to stimulate the adoption of a novel diagnostic technology, next generation sequencing, in the clinical setting. In her prior positions, Dr. Aziz was Vice President of Research and Development at Interleukin Genetics, Vice President of External Research at Point Therapeutics and Director of Translational Research at Novartis Institute of Biomedical Research. In her industry career, she has focused on personalized medicine, biomarkers, genetic tests, and development of drugs in cancer and diabetes. Prior to joining the biotechnology industry Dr. Aziz was an Assistant Professor at Harvard Medical School and Children’s Hospital in Boston where she discovered and characterized the function of a new gene involved in recessive polycystic kidney disease. Dr. Aziz received her Ph.D in molecular genetics at Massachusetts Institute of Technology where her doctoral research led to the discovery of a novel mechanism of regulation of translation of mRNAs.
Opportunities, Complexities and Challenges of NGS in Clinical Testing
Monday, 24 February 2014 at 09:00
Add to Calendar ▼2014-02-24 09:00:002014-02-24 10:00:00Europe/LondonOpportunities, Complexities and Challenges of NGS in Clinical TestingNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Many important advances in technologies for molecular analyses have fostered the rapid growth in molecular medicine. These technological advances include recombinant DNA techniques, genetic engineering, monoclonal antibody production, automated Sanger sequencing, polymerase chain reaction (PCR) including real time and digital PCR, microarrays and many more. The use of these technologies in routine testing of DNA, RNA, proteins for screening, diagnosing and prognosis of patient’s disease, and also in the development of new biologics and small molecule drugs have given rise to a science that 30 years ago was practically non-existent. Each of these technologies has led to significant advances, but one in particular, can be undoubtedly labeled as ‘disruptive’. Next generation sequencing (NGS), introduced in 2005, has revolutionized the field by increasing the speed at which the genome can be sequenced at a exponentially lower cost. Within 5 years of its introduction and widespread use in research, NGS is transforming molecular medicine.
Because it has a higher throughput and lower cost per base, NGS has been adopted into clinical testing far more rapidly than any other prior molecular technologies. The embracing of a new technology for routine diagnostics usually takes over 10 - 14 years or more. What is particularly intriguing about NGS’s rapid adoption into clinical testing is that compared to other molecular technologies it has a number of intricacies associated with its implementation that is unfamiliar to clinical laboratory. Dr. Aziz will address the opportunities, complexities and challenges of NGS clinical testing.
Add to Calendar ▼2014-02-24 00:00:002014-02-25 00:00:00Europe/LondonNext Generation Sequencing: Research to ClinicNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-02-24 09:00:002014-02-24 10:00:00Europe/LondonOpportunities, Complexities and Challenges of NGS in Clinical TestingNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
